Reactivation of Anticancer Immunity by Resetting Interorgan Crosstalk in Immune‐Suppressive Cells with a Nanoparticulated Anti‐Inflammatory Drug

The reactivation of anticancer immunity is a fundamental principle in cancer immunotherapy as evidenced by the use of immune checkpoint inhibitors (ICIs). While treatment with the ICIs is shown to have remarkable and durable therapeutic effects in the responders, the low objective response rate (

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Small (Weinheim an der Bergstrasse, Germany) Germany), 2023-04, Vol.19 (16), p.e2205131-n/a
Hauptverfasser:	Doi, Mizuki, Tanaka, Hiroki, Ohoto, Takara, Miura, Naoya, Sakurai, Yu, Hatakeyama, Hiroto, Akita, Hidetaka
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Inflammatory Agents - pharmacology Anti-Inflammatory Agents - therapeutic use Anticancer properties Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cancer Dexamethasone Dexamethasone - pharmacology Glucocorticoids Hematopoietic system Immunity Immunotherapy inflammation lipid nanoparticles Lipids Lymphocytes Myeloid-Derived Suppressor Cells - metabolism myeloid‐derived suppressor cells Nanoparticles Nanotechnology spleen Tumor Microenvironment tumor microenvironments
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The reactivation of anticancer immunity is a fundamental principle in cancer immunotherapy as evidenced by the use of immune checkpoint inhibitors (ICIs). While treatment with the ICIs is shown to have remarkable and durable therapeutic effects in the responders, the low objective response rate (
ISSN:	1613-6810 1613-6829
DOI:	10.1002/smll.202205131